Speaker's Highlight

  • Don Sin University of British Columbia, St. Paul Hospital (Canada)
    Kenneth R. Chapman Toronto General Hospital Research Institute (Canada)
  • Parameswaran Nair McMaster University (Canada)
    Carolyn Calfee UCSF (U.S.A.)
  • Gregory P. Downey University of Colorado School of Medicine (U.S.A.)
    David A. Schwartz University of Colorado School of Medicine (U.S.A.)
  • Neil Schluger Tuberculosis Control Branch, California Department of Public Health (U.S.A.)
    Nick Kim Critical Care & Sleep Medicine, University of California San Diego (U.S.A.)
  • Nicola Hananiah Baylor College of Medicine (U.S.A.)
    Jae-Joon Yim Seoul National University College of Medicine (Republic of Korea)
  • Koichiro Asano Tokai University School of Medicine (Japan)
    Diahn-Warng Perng Taipei Veterans General Hospital (Taiwan)
  • Konstantinos Kostikas University of Ioannina (Greece)
    Karin Klooster University Medical Center Groningen (Kingdom of the Netherlands)
  • The utility of exhaled nitric oxide in asthma monitoring

    Asthma monitoring increasingly combines symptoms, spirometry, reliever use, and biomarkers. Fractional exhaled nitric oxide, commonly called FeNO, adds a non-invasive view of type 2 airway inflammation. A patient may feel well while inflammation remains active, or report symptoms that arise mainly from dysfunctional breathing, reflux, infection, or another condition. FeNO can help place those findings in context.

    The measurement is quick, repeatable, and generally comfortable for adults and children who can follow the breathing instructions. Its greatest value comes from using it as part of a structured review rather than treating a single reading as a diagnosis or an automatic reason to change inhaled corticosteroid therapy.

    What FeNO reveals about airway inflammation

    Nitric oxide is produced in the respiratory epithelium, and production often rises with eosinophilic, type 2-driven inflammation. This inflammatory pattern is common in allergic asthma and may respond to corticosteroids. A raised FeNO level can therefore support the presence of steroid-responsive airway inflammation when the clinical picture is uncertain.

    FeNO does not measure airway narrowing directly. Spirometry is still needed to assess airflow limitation, bronchodilator reversibility, and lung function. Likewise, symptoms and exacerbation history remain essential because inflammation, obstruction, and perceived breathlessness do not always change at the same rate.

    A conference welcome message can provide useful context for the wider respiratory medicine community, where biomarker-guided care is considered alongside clinical assessment, research, and multidisciplinary practice.

    Using trends rather than isolated readings

    A baseline FeNO value obtained when asthma is stable can make later measurements more informative. A substantial rise from that personal baseline may indicate increasing type 2 inflammation, poor adherence, inadequate inhaler technique, allergen exposure, or a need to reassess the treatment plan. A fall after corticosteroid treatment may support an inflammatory response to that therapy.

    Absolute thresholds can assist interpretation, but they should not replace trend analysis. In adults, values below about 25 parts per billion are less supportive of active type 2 inflammation, while values above 50 ppb make it more likely. Intermediate results require greater attention to symptoms, lung function, medication use, and comorbid disease. Children have different reference points, and age, height, atopy, and current treatment affect the result.

    Where the test fits in routine care

    FeNO is especially useful when the diagnosis is uncertain, symptoms persist despite apparently normal spirometry, or clinicians need to investigate poor asthma control. It can help distinguish uncontrolled inflammation from problems such as incorrect inhaler technique, inconsistent medication use, vocal cord dysfunction, or non-asthmatic breathlessness.

    In established asthma, periodic readings may help identify loss of control before an exacerbation, evaluate response to inhaled corticosteroids, and support decisions about stepping treatment up or down. However, reducing therapy should involve sustained symptom control, stable lung function, and low exacerbation risk rather than a low FeNO result alone.

    Clinical situation Possible FeNO meaning Practical response
    Low reading with good control Little evidence of active type 2 inflammation Continue monitoring and review the broader control profile
    High reading with frequent symptoms Active eosinophilic inflammation may be present Check adherence and technique, assess triggers, and review anti-inflammatory treatment
    High reading without symptoms Subclinical inflammation or an alternative explanation Repeat or trend the result and consider future exacerbation risk
    Low reading with ongoing symptoms Symptoms may not be driven by type 2 inflammation Assess lung function, comorbidities, exposure, and other causes
    Falling reading after corticosteroids Likely reduction in steroid-responsive inflammation Interpret alongside symptoms, spirometry, and exacerbation history

    Factors that can distort interpretation

    Inhaled or systemic corticosteroids can lower FeNO, sometimes masking inflammation when medication has recently been started or increased. Poor adherence may produce a persistently high result, but the reading should prompt a respectful, non-judgmental medication review rather than an assumption that treatment has failed.

    Allergic rhinitis, recent viral infection, environmental allergens, and eosinophilic disorders can increase FeNO. Cigarette smoking may suppress it, while age, diet, exercise, and the technical quality of the breathing manoeuvre can also influence measurements. The same device, protocol, and timing are preferable when following change over time.

    A high FeNO level is not synonymous with asthma, and a low level does not exclude asthma. Neutrophilic or paucigranulocytic asthma may show little nitric oxide elevation, while symptoms can continue because of fixed obstruction, airway hyper-responsiveness, obesity, anxiety, or coexisting respiratory disease.

    Practical recommendations for clinicians

    • Record FeNO with symptom scores, exacerbation history, rescue medication use, and spirometry.
    • Confirm correct inhaler technique and explore adherence before escalating therapy because of a high result.
    • Repeat borderline or unexpected measurements under consistent testing conditions.
    • Interpret age, atopy, smoking status, infection, and corticosteroid exposure before applying thresholds.
    • Use changes over time to support decisions, never as a substitute for clinical judgment.

    Making biomarker monitoring useful

    For patients, the value of FeNO is easier to understand when the result is linked to a clear management question: Is inflammation active? Is the current anti-inflammatory treatment working? Is a worsening reading consistent with an increased risk of poor control? Explaining these questions can improve engagement and prevent unnecessary anxiety about a number.

    For healthcare teams, standardization matters. Staff should use validated equipment, document recent steroid exposure and smoking status, and ensure that the patient performs the manoeuvre correctly. Electronic records can display FeNO alongside peak flow, spirometry, symptom measures, and exacerbations, allowing a more complete view of changing disease activity.

    FeNO is most powerful as a decision-support tool within personalized asthma care. Add it to a consistent monitoring pathway, review unexpected results with the patient, and use the combined evidence to guide timely, evidence-based treatment decisions.

    Richard Russell Nuffield Department of Clinical Medicine, University of Oxford (United Kingdom)
  • Mona Bafadhel King’s College London (United Kingdom)
    David Jackson Guy’s and St Thomas’ Hospital, King’s College London (United Kingdom)
  • James Chalmers University of Dundee (United Kingdom)
    David Price University of Aberdeen (United Kingdom)

Copyright ⓒ APSR2022 all rights reserved

APSR Congress Privacy Policy